Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon May 20, 2022 12:33pm
129 Views
Post# 34698654

For Sh#t's and Giggles ...

For Sh#t's and Giggles ...Really - you decide not to follow them anymore because of that ?

"One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand."

You knew that.
You knew they were in opioid h-e-double-hockey-sticks.
You knew they would become insolvent.
You knew they got 3rd parties involved in restructuring discussions.

And now - as an investment bank - you decide it's time to focus elsewhere. 
Kind of funny !

-------------------

Oh ... and let's now sue these guys when they don't have a pot to p-ee in.  Go Endo Investors - sharp as nails they are. 

"The Buxton Helmsley Group, the New York City investment advisor to clients with financial interests in Endo International, today issued an open letter to shareholders and creditors of the Company, relating to corporate malfeasance and false statements of financial position."


I don't know, I think the company's information was clear and it said - stay away - nothing to see here.  We are in bouble-trouble !!!!!

Hey Chi-Chi ... you got any Endo to go with your Incyte shares ?  Where is that guy - hope he he didn't fall out of that slow boat heading to Miami from South America - heading to the Doctor's office.  Anyway !!!

: )



<< Previous
Bullboard Posts
Next >>